Literature DB >> 25574617

Foundation receives $3.3-billion windfall for Kalydeco.

Melanie Senior.   

Abstract

Mesh：

Substances：

Year:  2015        PMID： 25574617     DOI： 10.1038/nbt0115-8

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  2 in total

1.  Cystic fibrosis drug Vertex's latest triumph.

Authors:  Heidi Ledford
Journal:  Nat Biotechnol       Date:  2012-03-07       Impact factor: 54.908

2.  Pricing for orphan drugs: will the market bear what society cannot?

Authors:  Brian P O'Sullivan; David M Orenstein; Carlos E Milla
Journal:  JAMA       Date:  2013-10-02       Impact factor: 56.272
  2 in total
  1 in total

1.  Orphan Drug Pricing and Costs: A Case Study of Kalydeco and Orkambi.

Authors:  Aidan Hollis
Journal:  Healthc Policy       Date:  2019-08
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.